Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
Related Experiment Video
Updated: Nov 18, 2025
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Maria Celeste Cantone1, Alessandra Dicitore2, Giovanni Vitale1,2
1Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20129 Milan, Italy.
Abstract:
Neuroendocrine neoplasms (NENs) are a widely heterogeneous family of neoplasms arising from neuroendocrine cells, which are interspersed throughout the body. Despite NENs are relatively rare, their incidence and prevalence are constantly increasing probably due to the improvement in earlier diagnosis and patients' management. When surgery is not curative, particularly for patients with metastatic disease, several medical options are available. Somatostatin analogues (SSA) are the first-line medical therapy for well-differentiated NENs. Interestingly, the heterodimerization of somatostatin receptors (SSTs) with dopamine receptors (DRs) has been discovered in NENs. This phenomenon results in hybrid receptors with enhanced functional activity. On these bases, chimeric molecules embracing somatostatin and dopamine features have been recently developed. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding chimeric somatostatin-dopamine agonists as a new class of "magic bullet" in the therapy of NENs.
Insights
New chimeric agonists combining somatostatin and dopamine may offer a novel "magic bullet" treatment for neuroendocrine neoplasms (NENs). This review explores preclinical and clinical data on these promising therapies for NENs.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with increasing incidence.
- Current treatments for advanced NENs include somatostatin analogues (SSAs).
- The discovery of somatostatin receptor (SST) and dopamine receptor (DR) heterodimerization in NENs presents a new therapeutic target.
Purpose of the Study:
- To review preclinical and clinical data on chimeric somatostatin-dopamine agonists.
- To evaluate the potential of these novel agents as a targeted therapy for NENs.
Main Methods:
- Literature review of preclinical studies.
- Analysis of clinical trial data for chimeric agonists.
- Evaluation of receptor heterodimerization mechanisms in NENs.
Main Results:
- Chimeric molecules combining somatostatin and dopamine features have been developed.
- These agents target hybrid somatostatin-dopamine receptors with enhanced activity.
- Early data suggest potential efficacy in NEN treatment.
Conclusions:
- Chimeric somatostatin-dopamine agonists represent a promising new therapeutic class for NENs.
- Further clinical investigation is warranted to establish their role in NEN management.
- Targeting receptor heterodimerization offers a novel strategy for NEN therapy.
Related Concept Videos
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists